Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis
ConclusionsThe CSG performed well at the 30% threshold. Its high NPV suggests that the test is suitable to guide PQ treatment, and the high LR+ and low LR − render the test suitable to confirm and exclude G6PDd. Further operational studies are needed to confirm the utility of the test in remote endemic settings.
Source: PLoS Medicine - Category: Internal Medicine Authors: Benedikt Ley Source Type: research
More News: African Health | Biotechnology | Endemics | G6PD | Internal Medicine | Ireland Health | Malaria | Men | Study